Well it appears more work in the ED field...lot of money....BD
VIVUS, Inc. (NASDAQ: VVUS) announced that it has entered into a $30 million funding collaboration with Deerfield Management ("Deerfield"). Under the terms of the agreements, Deerfield will provide funds for the phase 3 program for avanafil, a fast-acting, highly selective, phosphodiesterase type 5 inhibitor (PDE5i) for the treatment of erectile dysfunction (ED). The $30 million in funding will be provided by Deerfield from two sources: $20 million under a Royalty and Funding Agreement and $10 million from the sale of VIVUS common stock. VIVUS has granted Deerfield a royalty interest on sales of MUSE®, our product currently marketed for the treatment of ED.
0 comments :
Post a Comment